BTIG Research initiated coverage on Opus Genetics with a new price target
$IRD
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2026 | $15.00 | Overweight | Cantor Fitzgerald |
| 3/16/2026 | $10.00 | Outperform | Oppenheimer |
| 1/20/2026 | $7.00 | Buy | BTIG Research |
| 12/10/2025 | $9.00 | Buy | B. Riley Securities |
| 11/25/2025 | $7.00 | Overweight | Piper Sandler |
| 10/29/2025 | $8.00 | Outperform | Wedbush |
| 10/16/2025 | $9.00 | Buy | Chardan Capital Markets |
| 4/11/2025 | $6.00 | Buy | Craig Hallum |
RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences. Leerink Global Healthcare Conference Date: Tuesday, March 10, 2026Time: 3:00 p.m. ETLocation: Miami, FL Citizens Life Sciences Conference Date: Wednesday, March 11, 2026Time: 2:50 p.m. ETLocation: Miami, FL RBC Capital Markets Global Ophthalmology Conference Date: Wednesday, March 25, 2026Time: 11:45 a.m. ETLoc
Cantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00
Oppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00
BTIG Research initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $7.00
DEF 14A - Opus Genetics, Inc. (0001228627) (Filer)
S-3 - Opus Genetics, Inc. (0001228627) (Filer)
PRE 14A - Opus Genetics, Inc. (0001228627) (Filer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus' deep pipeline in rare inherited retinal diseases -- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -- Funding from prominent healthcare investors expected to extend cash runway into 2028 - RESEARCH TRIANGLE PARK, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive three-month data from the pediatric cohort
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs - RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, In
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial
SC 13D - Opus Genetics, Inc. (0001228627) (Subject)